EMA validates Biogen and AbbVie’s MAA for Zinbryta to treat multiple sclerosis
The validation of MAA confirms that the submission is complete and signifies the start of the review process by the EMA’s Committee for Medicinal Products for Human Use
Daiichi Sankyo has entered a collaboration with France-based Waiv, which aims to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme.
The open label, multi-dose, safety and pharmacokinetic (PK) study is expected to enroll around 46 subjects with schizophrenia or schizoaffective disorder. Relday has been designed to offer potentially
Zafatek (trelagliptin succinate) controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, incretin hormones